Guideline and Consensus
Guideline for the diagnosis and management of hyperuricemia and gout in China(2019)
Chinese Society of Endocrinology, Chinese Medical Association
Published 2020-01-25
Cite as Chin J Endocrinol Metab, 2020, 36(1): 1-13. DOI: 10.3760/cma.j.issn.1000-6699.2020.01.001
Abstract
The prevalence of hyperuricemia and gout is increasing dramatically in China in recent years, which has urgently prompted a clinical practice guideline based on evidences from Chinese population. The Chinese Society of Endocrinology, Chinese Medical Association, began to prepare the guideline in 2018 and completed it in 2019. The guideline was developed following the standard procedures of evidence-based clinical practice guideline, with GRADE method, by multidisciplinary experts including methodologists. A systemic review of the literature concerning all aspects of diagnosis and management of hyperuricemia and gout was performed. Three overarching principles and recommendations for 10 key clinical questions were generated. The guideline also recommended for the first time the concept, diagnosis and treatment of subclinical gout and refractory gout, problems addressing urine alkalization, optimized drug options on co-morbidities. This guideline may provide the best strategy on hyperuricemia and gout management for physicians and stakeholders in China.
Key words:
Hyperuricemia; Gout; Diagnosis; Management; Guideline
Contributor Information
Chinese Society of Endocrinology, Chinese Medical Association